Zura Bio Limited (ZURA)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	188.22 mm	188.22 mm	188.22 mm	188.22 mm	188.22 mm	188.22 mm
Cash burn (monthly)	74.00 k	(no burn)	6.90 mm	4.31 mm	1.88 mm	1.78 mm
Cash used (since last report)	374.81 k	n/a	34.95 mm	21.81 mm	9.54 mm	8.99 mm
Cash remaining	187.85 mm	n/a	153.27 mm	166.41 mm	178.68 mm	179.23 mm
Runway (months of cash)	2538.5	n/a	22.2	38.7	94.8	101.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

ZURA institutional ownership history Ownership history

98.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	85	64	+32.8%
Opened positions	27	21	+28.6%
Closed positions	6	6	–
Increased positions	30	21	+42.9%
Reduced positions	9	9	–

13F shares	Current	Prev Q	Change
Total value	150.66 bn	114.89 bn	+31.1%
Total shares	64.22 mm	63.28 mm	+1.5%
Total puts	325.50 k	0.00	NEW
Total calls	350.00 k	0.00	NEW
Total put/call ratio	0.9	–	–

Largest owners	Shares	Value	Change
Venrock Healthcare Capital Partners III	6.85 mm	$31.73 mm	+7.1%
Hana Immunotherapeutics	5.40 mm	$0.00	0.0%
Suvretta Capital Management	4.86 mm	$19.74 bn	0.0%
Access Industries Management	4.39 mm	$13.96 mm	0.0%
ADAR1 Capital Management	3.77 mm	$15.31 bn	NEW
Ewon Comfortech	3.65 mm	$0.00	0.0%
Deep Track Capital	3.28 mm	$13.33 bn	0.0%
Great Point Partners	3.26 mm	$13.25 bn	-29.7%
Ra Capital Management	3.22 mm	$13.06 bn	0.0%
PFE Pfizer	2.97 mm	$0.00	0.0%

Largest transactions	Shares	Bought/sold	Change
VR Adviser	2.02 mm	-4.00 mm	-66.4%
Athanor Capital	1.00 mm	-3.80 mm	-79.1%
ADAR1 Capital Management	3.77 mm	+3.77 mm	NEW
Braidwell	2.47 mm	+2.47 mm	NEW
BlackRock	2.37 mm	+2.37 mm	NEW
Great Point Partners	3.26 mm	-1.38 mm	-29.7%
BLK BlackRock	0.00	-1.20 mm	EXIT
StemPoint Capital	1.04 mm	+1.04 mm	NEW
Armistice Capital	1.50 mm	-1.02 mm	-40.6%
Sphera Funds Management	738.72 k	+738.72 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ZURA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
9 Dec 24	Parvinder Thiara	Share Option Class A Ordinary Shares	Grant	Acquire A	No	No	2.76	117,000	322.92 k	117,000
9 Dec 24	Jarrett Jennifer	Share Option Class A Ordinary Shares	Grant	Acquire A	No	No	2.76	117,000	322.92 k	117,000
9 Dec 24	Neil Murray Hamilton Graham	Share Option Class A Ordinary Shares	Grant	Acquire A	No	No	2.76	117,000	322.92 k	117,000
4 Sep 24	Someit Sidhu	Class A Ordinary Shares	Other	Dispose J	Yes	No	0	593,055	0.00	242,055
24 Aug 24	Someit Sidhu	Class A Ordinary Shares	Grant	Acquire A	No	No	0	721,971	0.00	2,807,389
24 Aug 24	Someit Sidhu	Class A Ordinary Shares	Grant	Acquire A	Yes	No	0	835,110	0.00	242,055
23 Aug 24	Someit Sidhu	Warrants Class A Ordinary Shares	Sale back to company	Dispose D	No	No	11.5	2,406,573	27.68 mm	0
23 Aug 24	Someit Sidhu	Warrants Class A Ordinary Shares	Sale back to company	Dispose D	Yes	No	11.5	2,783,701	32.01 mm	0
23 Aug 24	Verender S. Badial	Class A Ordinary Shares	Grant	Acquire A	No	No	0	126,155	0.00	517,519
23 Aug 24	Verender S. Badial	Warrants Class A Ordinary Shares	Sale back to company	Dispose D	No	No	11.5	420,519	4.84 mm	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

HC Wainwright & Co. Reiterates Neutral on Zura Bio, Maintains $5 Price Target

24 Dec 24

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Zura Bio (NASDAQ:ZURA) with a Neutral and maintains $5 price target.

Cantor Fitzgerald Reiterates Overweight on Zura Bioto Overweight

11 Dec 24

Cantor Fitzgerald analyst Josh Schimmer reiterates Zura Bio (NASDAQ:ZURA) from Overweight to Overweight.

Press releases

From Benzinga Pro

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

24 Feb 25

Zura Bio Limited (NASDAQ:ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

23 Dec 24

TibuSURE is the first clinical trial designed to investigate anti-BAFF and IL-17 pathways in systemic sclerosis. TibuSURE launches with the initiation of its first clinical site. Zura Bio Limited (NASDAQ:ZURA)